From Diagnosis to Discovery: How Biospecimens Power Rare Disease Therapeutics

Photo credit: CDC/ Dr. David M. Morens, Dr. Steve Thacker

Understanding a rare disease’s molecular basis, and turning that understanding into effective therapies, can take years or even decades. It requires coordinated work across basic science, translational research, preclinical development, clinical trials, and regulatory approval. At every stage, high-quality biospecimens are essential tools: they enable discoveries, test hypotheses, and help teams make confident go/no-go decisions. Rare diseases affect small patient populations, which makes traditional clinical development harder. That makes biospecimen-based research even more critical. It often determines whether a therapeutic program can move forward, or stalls from a lack of biological understanding or validation tools.

Recent analyses show that about 95% of rare diseases still lack an approved therapy, despite decades of research investment. Scientific challenges play a role, but so do limits on accessing the right biospecimens for research, validation, and clinical development. Better biospecimen collection strategies can help close this gap. Understanding how biospecimens power each stage of the research continuum shows where investing in biospecimen infrastructure can help. That investment can speed up progress toward treatments for diseases that are currently untreatable.

Mechanistic Research: Unlocking Disease Biology

Therapeutic development starts with understanding disease mechanisms. For rare genetic disorders, the first step is finding the gene involved and figuring out what goes wrong when it’s mutated. But going from a genetic diagnosis to a therapeutic strategy takes deeper insight, and that insight comes from studying patient biospecimens.

Take lysosomal storage diseases like Fabry disease, caused by mutations in the GLA gene that codes for the alpha-galactosidase A enzyme. Researchers have known the genetic cause for decades. But fully understanding how a deficiency in this enzyme leads to cardiac hypertrophy, kidney failure, nerve pain, and stroke requires studying patient biospecimens. Plasma samples from confirmed Fabry patients show a buildup of substrates like globotriaosylceramide (Gb3) and lyso-Gb3, documenting how these substances accumulate throughout the body. Immune cell profiling using PBMCs supports gene expression studies that link this substrate buildup to inflammation and downstream tissue scarring.

These insights from patient biospecimens matter for therapeutic strategy. If substrate buildup alone caused all the disease’s problems, reducing that substrate or replacing the missing enzyme might fully solve it. But biospecimen research showing chronic inflammation, scarring, and other downstream effects suggests combination strategies — treating both the substrate buildup and its downstream effects — may work better.

For rare diseases where the genetic cause is unknown or poorly understood, biospecimen-based discovery plays an even bigger role. Whole-exome or whole-genome sequencing from whole blood supports gene discovery and tracking how variants run in families. Complementary multi-omic work can draw on plasma, scalable bulk plasma for assay development, and serum for protein and inflammation marker profiling.

Target Identification and Validation

Once researchers understand a disease mechanism, they still need to confirm that a specific molecular target can be treated. Confirming that requires extensive validation using patient biospecimens. A good therapeutic target should be clearly tied to the disease, safely treatable without unacceptable side effects, and reachable with the tools available.

Biospecimen-based validation can show that a protein is out of balance in patient samples compared to healthy controls. It can also show that the protein tracks with disease severity, and that it returns to normal when treated in relevant models. For rare metabolic disorders, showing that a candidate therapeutic enzyme can break down substrates measurable in plasma or serum gives critical validation before committing to a costly program.

Gene therapy development for rare diseases depends heavily on this kind of biospecimen-based validation. Programs often compare enzyme restoration, or shifts in downstream biomarkers, against reference values built from patient-derived biofluids and immune cells. When programs need larger volumes of leukocytes for method development or cell-based assays, human leukopaks can support standardized workflows.

Biomarker Discovery: Creating Tools for Development and Monitoring

Biomarkers serve several key roles in rare disease drug development:

• Diagnostic biomarkers help identify affected patients, and can even support screening before symptoms appear.
• Prognostic biomarkers predict how a disease will progress, helping identify patients who would benefit most from early treatment.
• Predictive biomarkers show which patients will respond to a specific therapy, supporting precision medicine.
• Pharmacodynamic biomarkers show that a therapy is reaching its target and having a biological effect — giving early evidence that it’s working, before clinical benefit is even measurable.

Turning a candidate biomarker into a clinically validated tool takes extensive biospecimen resources. Discovery efforts typically use broad approaches like proteomics, metabolomics, or transcriptomics, comparing biospecimens from affected patients against matched controls. This can turn up hundreds or thousands of candidates. Researchers then narrow these down based on biological plausibility, how easy they are to test for, and validation in independent sample sets.

Biomarker development for Gaucher disease has gone through several rounds of refinement. Chitotriosidase rises sharply in many Gaucher patients and is widely used to monitor treatment response. But it has limits. Some populations carry genetic variants that cause a deficiency in it, and it isn’t fully specific to Gaucher disease. Biospecimen-based research has since identified complementary biomarkers like CCL18/PARC and lyso-GL1, enabling panel-based approaches that don’t rely on any single marker. These programs commonly rely on standardized plasma and serum collections so results are comparable across platforms.

Longitudinal biospecimen collections from natural history studies are especially valuable for validating biomarkers. Serial sampling shows whether a biomarker changes consistently as the disease progresses, responds appropriately to treatment, and correlates with outcomes that matter to patients.

Preclinical Development: Validating Models and Approaches

Animal models, patient-derived cell lines, and other lab systems are essential tools for preclinical rare disease research. But researchers must validate how well they reflect human disease using patient biospecimens. A researcher developing a mouse model of mucopolysaccharidosis (MPS), for example, needs to show that the model reproduces the biochemical features seen in human disease. That includes a buildup of glycosaminoglycans and elevated disease biomarkers measurable in biofluids.

This validation depends on access to well-characterized biospecimens from confirmed patients. Researchers can set biofluid benchmarks using plasma and serum. They can study cellular and immune pathways using PBMCs and immune subsets like CD3+ T cells or CD56+ NK cells when deeper mechanistic detail is needed.

For gene therapy and cell therapy development, preclinical validation of vector design, delivery, and dosing often relies on comparisons to human biospecimen data. Researchers compare enzyme activity and downstream biomarker levels in treated models to the ranges seen in healthy controls and affected patients. That comparison helps them judge whether the achieved levels are likely to help patients.

Clinical Trial Design: Endpoints, Inclusion Criteria, and Power Calculations

Designing clinical trials for rare diseases is uniquely hard. Patient populations are small, symptoms vary widely between patients, natural history data is limited, and using placebo controls raises ethical concerns when treatments already exist. Biospecimen-based research helps address these challenges. It enables biomarker-based patient grouping, helps identify the right trial endpoints, and provides natural history comparisons for trials that can’t use a control arm.

Hunter syndrome (MPS II), an X-linked lysosomal storage disease, shows a wide range of symptoms from patient to patient. Trials that enroll a mixed population often need larger sample sizes to detect a treatment effect, but grouping patients by genetic and biomarker profile can reduce that variability. Programs backed by strong biospecimen repositories benefit from linked clinical data and, where available, genomic data that improves feasibility.

Trial designs increasingly use biomarker endpoints alongside clinical measures, especially in early-phase studies. Showing a reduction in accumulated substrates measurable in plasma can offer early evidence that a drug works. Longer studies then determine whether that biomarker improvement leads to real clinical benefit.

For ultra-rare diseases affecting fewer than one hundred people worldwide, a traditional randomized controlled trial may not be possible at all. Natural history studies with thorough biospecimen collection create external comparison groups, giving context for interpreting results in small treated groups.

Regulatory Approval: Evidence Standards and Patient Access

Regulators have built frameworks that account for the evidence challenges of small patient populations. Accelerated approval pathways and orphan-drug incentives create earlier paths to patient access. But they still require solid evidence of safety and effectiveness, often supported by biomarkers when clinical endpoints are hard to measure in small trials.

Biomarker evidence from biospecimens supports regulatory submissions by showing that a drug reaches its target and has a plausible biological effect. For advanced therapies like gene therapies, showing that disease-relevant biomarkers stay normal over time in blood-derived samples can reassure regulators that the biological effect will last.

After approval, biospecimen-based research continues to support treatment optimization and real-world evidence. Registries that collect biospecimens from treated patients help track how long benefits last, identify which patient subgroups respond best, and investigate side effects.

Precision Medicine: Matching Patients to Therapies

As more therapies become available, choosing the right one for each patient matters more than ever. Enzyme replacement, substrate reduction, chaperone therapy, and gene therapy each come with their own advantages and limits. Companion diagnostics and predictive biomarkers, built from biospecimen research, help match patients to the approach most likely to help them.

For Fabry disease, chaperone therapies stabilize certain mutant forms of the enzyme, offering an alternative to enzyme replacement. But how well they work depends on the patient’s specific mutation. Biospecimen-based assays can test how a patient’s cells or immune cells respond to a chaperone. This helps select patients likely to benefit and avoid exposing others to a treatment that won’t work.

Pharmacogenomics is playing a bigger role in rare disease treatment, but using it safely still requires validation with biospecimens from well-characterized patient groups.

From Study Design to Receipt of Samples: Comprehensive Biospecimen Solutions

Supporting rare disease therapeutic development across this full continuum takes biospecimen infrastructure built for flexibility, quality, and thorough annotation. Researchers often need a range of sample types, including plasma, serum, PBMCs, whole blood, and specialized samples for translational or tissue-based studies.

When a program needs tissue-level investigation, samples like skin punch biopsies can support cell model development, fibroblast line creation, and pathway studies. When inflammatory or joint symptoms are part of the disease, matrices like synovial fluid can add useful signal for biomarker and mechanism work.

Longitudinal sample sets that follow patients over time reveal natural history, biomarker trends, and treatment response patterns that a single snapshot can’t show. Matched sample sets — multiple specimen types collected from the same patient at the same time — support analysis across different biological compartments.

Sanguine’s rare disease biospecimen capabilities support therapeutic development across this full spectrum. Our direct-to-patient collection model lets us recruit geographically diverse cohorts across the United States. Our quality management systems protect sample integrity from study design to receipt of samples, and our annotation protocols capture the clinical and molecular context researchers need.

---

References

1. Health Lumen. Rare Disease Day 2025: Reflecting on a Year of Progress and the Challenges That Lie Ahead. Published February 28, 2025. Accessed December 10, 2024.
2. Delve Insight. Lysosomal Storage Disorders: A Rare Disease Overview. Published 2024. Accessed December 10, 2024.
3. Lysosomal Disease Research and Treatment Center. 2024: A Year in Review — Highlights from the LDRTC Clinical Trials and Research Unit. Newsletter. Published 2024. Accessed December 10, 2024.
4. National Institutes of Health. RFA-FD-24-024: Natural History, Clinical Outcome, and Biomarker Study. NIH Grants; 2024. Accessed December 10, 2024.
5. Kido J, Sugawara K, Nakamura K. Gene therapy for lysosomal storage diseases: current clinical trial prospects. Front Genet. 2023;14:1064924. doi:10.3389/fgene.2023.1064924
6. Rare Diseases Clinical Research Network. NIH Announces Funding to Establish and Strengthen Rare Disease Research Groups. Published October 29, 2024. Accessed December 10, 2024.